QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
NSW Govt to launch science and innovation fund
The fund will be used to coordinate strategic investments, deliver on government priorities and...
DKSH brings Bioyond Robotics' lab automation products Down Under
DKSH will provide distribution of the Bioyond Robotics portfolio of AI-driven autonomous...
Immunologist wins GSK Award for respiratory virus research
Award winner Professor Katherine Kedzierska seeks to answer an important question: why do some...
